<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867618</url>
  </required_header>
  <id_info>
    <org_study_id>AAAP5661</org_study_id>
    <nct_id>NCT02867618</nct_id>
  </id_info>
  <brief_title>Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma</brief_title>
  <official_title>Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, phase I/II, dose-escalation study in the initial phase I followed by a&#xD;
      phase II.&#xD;
&#xD;
      The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and&#xD;
      dose limiting toxicity (DLT) of the combinations of TGR-1202 and carfilzomib in participants&#xD;
      with relapsed and refractory (R/R) non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). The&#xD;
      safety and toxicity of this combination will be evaluated throughout the entire study.&#xD;
&#xD;
      If the combination of TGR-1202 and carfilzomib is found to be feasible and an MTD is&#xD;
      established, the phase II part of the study will be initiated.&#xD;
&#xD;
      Phase II will consist of a 2-stage design of the combination of TGR-1202 and carfilzomib for&#xD;
      participants with R/R NHL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dysregulated c-Myc is associated with resistance to chemotherapy and poor survival in&#xD;
      aggressive lymphomas. Novel strategies that target this biology could markedly improve the&#xD;
      outcome of these participants. To date no drugs that directly target Myc have been approved&#xD;
      for cancer treatment. Recent results by Deng et al. (Blood. 2017 Jan 5. PMID: 27784673)&#xD;
      described a highly synergistic regimen discovered in preclinical models, through combining&#xD;
      TGR-1202, an investigational drug that inhibits PI3K delta, and carfilzomib, a drug approved&#xD;
      by the FDA for multiple myeloma. Importantly, the combination of TGR-1202 and carfilzomib&#xD;
      acts by potently silencing the translation of c-Myc and inducing apoptosis in many cell lines&#xD;
      and primary lymphoma cells representing broad histological subtypes of lymphoma. These&#xD;
      results suggest that TGR-1202 and carfilzomib may be highly effective in relapsed and&#xD;
      refractory lymphoma where c-Myc plays a key pathological role.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution&#xD;
  </why_stopped>
  <start_date type="Actual">October 16, 2016</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) (Phase 1) - TGR-1202 Only</measure>
    <time_frame>9 months</time_frame>
    <description>The highest dose of the study treatment that does not cause unacceptable side effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (Phase 2)</measure>
    <time_frame>9 months</time_frame>
    <description>Defined as best response (complete response and partial response) by 4 cycles.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma, Non-hodgkin</condition>
  <arm_group>
    <arm_group_label>Carfilzomib + TGR-1202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202</description>
    <arm_group_label>Carfilzomib + TGR-1202</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TGR-1202</intervention_name>
    <description>Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib</description>
    <arm_group_label>Carfilzomib + TGR-1202</arm_group_label>
    <other_name>(formerly) RP-5264</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Target Population Phase I: Patients with relapsed or refractory NHL and HL Phase II:&#xD;
        Patients with relapsed or refractory NHL&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Phase I: Patients must have histologically confirmed R/R NHL or HL (defined by World&#xD;
             Health Organization (WHO) criteria). Patients with chronic lymphocytic leukemia (CLL)&#xD;
             and small lymphocytic lymphoma (SLL) are eligible. In addition, patients with NHL&#xD;
             other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior&#xD;
             therapies. Patients with DLBCL and HL will be eligible if there is no available&#xD;
             standard therapy.&#xD;
&#xD;
          -  Phase II: Patients must have histologically confirmed R/R NHL (as defined by WHO&#xD;
             criteria). Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must&#xD;
             have received at least 2 prior therapies. Patients with DLBCL will be eligible if&#xD;
             there is no available standard therapy.&#xD;
&#xD;
          -  Must have received front line chemotherapy. No upper limit for the number of prior&#xD;
             therapies&#xD;
&#xD;
          -  Evaluable Disease in the Phase I, and measurable disease in the Phase II&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function&#xD;
&#xD;
          -  Adequate Contraception&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to&#xD;
             entering the study or those who have not recovered from adverse events due to agents&#xD;
             administered more than 2 weeks earlier. Systemic steroids that have not been&#xD;
             stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of&#xD;
             the study drugs. No other investigational agents are allowed.&#xD;
&#xD;
          2. History of allergic reactions to TGR-1202 or carfilzomib&#xD;
&#xD;
          3. Uncontrolled inter-current illness&#xD;
&#xD;
          4. Pregnant women&#xD;
&#xD;
          5. Nursing women&#xD;
&#xD;
          6. Current malignancy or history of a prior malignancy&#xD;
&#xD;
          7. Patient known to be Human Immunodeficiency Virus (HIV)-positive&#xD;
&#xD;
          8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changchun Deng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Clinical Medicine and Experimental Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center - Center for Lymphoid Malignancies</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <results_first_submitted>June 28, 2021</results_first_submitted>
  <results_first_submitted_qc>June 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2021</results_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02867618/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 out of 14 subjects were enrolled (consented) but not accrued into study and did not receive study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Carfilzomib + TGR-1202</title>
          <description>Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.&#xD;
Carfilzomib: Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202&#xD;
TGR-1202: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>3 out of 14 subjects were enrolled but not accrued into study; however, baseline information was collected for all 14 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Carfilzomib + TGR-1202</title>
          <description>Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.&#xD;
Carfilzomib: Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202&#xD;
TGR-1202: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-21 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>22-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) (Phase 1) - TGR-1202 Only</title>
        <description>The highest dose of the study treatment that does not cause unacceptable side effects.</description>
        <time_frame>9 months</time_frame>
        <population>PI left the institution, study data was not complete or analyzed for Carfilzomib (Phase 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib + TGR-1202</title>
            <description>Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.&#xD;
Carfilzomib: Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202&#xD;
TGR-1202: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) (Phase 1) - TGR-1202 Only</title>
          <description>The highest dose of the study treatment that does not cause unacceptable side effects.</description>
          <population>PI left the institution, study data was not complete or analyzed for Carfilzomib (Phase 2).</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR) (Phase 2)</title>
        <description>Defined as best response (complete response and partial response) by 4 cycles.</description>
        <time_frame>9 months</time_frame>
        <population>The data was not collected or analyzed due to PI leaving the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib + TGR-1202</title>
            <description>Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.&#xD;
Carfilzomib: Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202&#xD;
TGR-1202: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) (Phase 2)</title>
          <description>Defined as best response (complete response and partial response) by 4 cycles.</description>
          <population>The data was not collected or analyzed due to PI leaving the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 1 year post study treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carfilzomib + TGR-1202</title>
          <description>Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.&#xD;
Carfilzomib: Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202&#xD;
TGR-1202: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ana Ignat</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-3612</phone>
      <email>ai2111@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

